At Beta Bionics, we are developing a bionic pancreas called the iLet® – a fully integrated medical device that is designed to reduce the burden and cost of diabetes care by automatically and autonomously managing blood sugar levels 24/7 in people with type 1 diabetes (T1D). To be clear, the iLet bionic pancreas is not yet commercially available because it has not yet been cleared by the FDA or any other regulatory body. We will have to obtain regulatory clearances before we can offer the iLet for commercial sale. In 2020 the insulin only bionic pancreas pivotal trial is planned to begin clinical testing of the insulin only iLet. However, that is not the same as receiving regulatory clearance for commercial sale. Our goal is to use the results of the insulin only bionic pancreas pivotal trial to support the market application of the insulin only iLet in 2021.